Loading
Neuronetics, Inc. Stock: price and insider trades · United States
1 insider bought €38k of shares over the last 90 days, the latest filed 17 Aug 2026.
Neuronetics, Inc.: what insiders have been doing
Neuronetics, Inc., classified in the Healthcare & Pharma sector, is a listed company based in Malvern, United States, founded in 2003. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, 45 filings were filed, from 14 insiders.
Purchases and sales both appear in the filings: 10 purchases (1 insider, €3.0M) and 10 sales (3 insiders, €231k). Netting one side against the other leaves €2.7M of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €711k, bought by Chernett Jorey and made public on 20 March 2026. On the buying side, the filings list 1 major shareholder among the declarants.
The clock since the last published purchase (17 August 2026) now reads 62 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 45 filings, this issuer sits above that mark. Since 2021, the database holds 37 purchases and 75 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 149.2 m USD of revenue and -39.0 m USD of net income.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
190
Thresholds
n/a
Buy Volume
€4M
37 ops. · all time
Sell Volume
€6M
75 ops. · all time
Who traded when
BuySaleJorey Chernett10 buys
Macan William Andrew9 sales
Sullivan Keith J6 sales
Furlong Stephen5 sales
Madryn Asset Management, LP1 sale
Steven Pfanstiel1 sale
Since the insiders bought
- -38.1%Entry US$3.15 · Close 15 Oct 2026 US$1.95
- +267.9%Entry US$0.78 · Close at T+365 US$2.87
- +332.1%Entry US$0.78 · Close at T+365 US$3.37
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,469 of 24,148 companies
18.6
score / 100
Value11
Quality26
FCF yld-14%
Earn yld-26%
EV/EBITDA·
ROE-116%
Gross mgn48%
Net mgn-26%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.95
Analyst consensus
4 analysts1.25/5
US$5.00Target US$5.75(+195%)US$7.00
Income statement
RevenueUS$149.2M
Gross profitUS$72.3M48% margin
EBITDA-US$28.1M-19% margin
Net income-US$39M-19.6% margin
Valuation
PER (forward)-5.7x
P/Book8.3x
Beta1.20
Balance sheet & cash
Market capUS$148.6M
Total debtUS$90.3M
Free Cash Flow-US$21.2M
Debt / Equity400%
Profitability & ownership
ROE-116.1%
ROA-10.5%
% insiders32.8%
% institutions54.0%
Last declaration on 19 August 2026
Declarations190 total
149,891 shares@ US$3.09510.22% mcap28.2% of flowCommonSEC144:0001959173-26-006219
121,033 shares@ US$3.2080.18% mcap23.6% of flowCommonSEC144:0001959173-26-006183
14,000 shares@ US$3.160.021% mcap1.3% of flowCommon StockSEC:0000921895-26-002204:0
Canonical exit: 12 Nov 2026 (T+90)
35,000 shares@ US$1.780.030% mcap1.8% of flowCommon StockSEC:0000921895-26-001811:0
Canonical exit: 12 Oct 2026 (T+90)
2,934 sharesCommon StockSEC:0001193125-26-274343:0
34,932 sharesCommon StockSEC:0001193125-26-274343:1
4,634 sharesCommon StockSEC:0001193125-26-274343:2
42,164 shares@ US$1.28890.022% mcap2.5% of flowCommonSEC144:0001959173-26-004449
30,000 shares0Common StockSEC:0002044406-26-000002:0
36,250 shares0Common StockSEC:0001218713-26-000002:0
30,000 shares0Common StockSEC:0001238659-26-000002:0
30,000 shares0Common StockSEC:0002004858-26-000002:0
100,000 shares@ US$1.580.063% mcap4.5% of flowCommon StockSEC:0000921895-26-001056:0
Canonical exit: 19 Jul 2026 (T+90)
100,000 shares@ US$1.510.060% mcap4.3% of flowCommon StockSEC:0000921895-26-001056:1
Canonical exit: 20 Jul 2026 (T+90)
337,312 shares0Common StockSEC:0001193125-26-138142:0
337,312 shares0Common StockSEC:0001193125-26-138142:1
385,442 shares@ US$1.2514.2% of flowCommon StockSEC:0000921895-26-000835:0
Canonical exit: 28 Jun 2026 (T+90)
500,000 shares@ US$1.3519.7% of flowCommon StockSEC:0000921895-26-000822:0
Canonical exit: 25 Jun 2026 (T+90)
125,000 shares@ US$1.405.1% of flowCommon StockSEC:0000921895-26-000813:0
Canonical exit: 23 Jun 2026 (T+90)
16,431 shares@ US$1.34100.0% of flowCommon StockSEC:0001193125-26-122298:0
46,289 shares@ US$1.342.8% of flowCommon StockSEC:0001193125-26-122295:0
16,005 shares@ US$1.341.3% of flowCommon StockSEC:0001193125-26-122290:0
1,500,000 shares0Common StockSEC:0001563602-26-000006:0
169,472 shares@ US$1.417.0% of flowCommon StockSEC:0001193805-26-000308:0
Canonical exit: 18 Jun 2026 (T+90)
25 of 190 declarations
About Neuronetics, Inc.
Neuronetics, Inc. (ticker: STIM) is a U.S.-based medical technology company listed on the NASDAQ market in the United States. The company focuses on the design, development, commercialization, and support of non-invasive neurohealth treatments, with a primary emphasis on mental health disorders. Headquartered in Malvern, Pennsylvania, Neuronetics is positioned as a commercial-stage, vertically integrated healthcare business that combines device sales, clinical services, and recurring revenue streams tied to treatment delivery and patient access. ([ir.neuronetics.com](https://ir.neuronetics.com/news-releases/news-release-details/neuronetics-reports-first-quarter-2026-financial-and-operating?utm_source=openai))
Neuronetics was founded in the late 2000s and built its business around its flagship product, NeuroStar Advanced Therapy, a transcranial magnetic stimulation (TMS) system used in office-based care settings. NeuroStar is FDA-cleared for adult patients with major depressive disorder who have not achieved satisfactory improvement from prior antidepressant medication in the current episode. That regulatory clearance is strategically important because it supports physician adoption, payer engagement, and broader clinical acceptance in a still-developing treatment category. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1227636/000110465926029004/stim-20251231x10k.htm?utm_source=openai))
Read moreShow less
The company’s operating model is centered on three main economic drivers: sales of NeuroStar systems, services and clinic-related revenue, and other revenues associated with system utilization and support. This hybrid model allows Neuronetics to participate both in the upfront sale of capital equipment and in the ongoing economics of therapy delivery. Recent company disclosures indicate that its clinic business has been a meaningful growth engine, while management has also highlighted improvements in operating cash flow and a stronger commercial cadence in the U.S. market. ([ir.neuronetics.com](https://ir.neuronetics.com/news-releases/news-release-details/neuronetics-reports-first-quarter-2026-financial-and-operating?utm_source=openai))
From a competitive perspective, Neuronetics is one of the better-known branded players in TMS for depression, operating in a market that remains underpenetrated relative to the size of the addressable patient population. The company has been strengthening its commercial footprint through partnerships designed to expand patient access and provider reach. A notable example is its three-year exclusive partnership with Elite DNA Behavioral Health, one of Florida’s largest and fastest-growing behavioral health networks, aimed at making NeuroStar the sole TMS device across that network’s sites. Neuronetics also expanded scale through the acquisition of Greenbrook TMS, which broadened its clinic footprint and increased exposure to recurring therapy revenue. ([ir.neuronetics.com](https://ir.neuronetics.com/news-releases/news-release-details/neuronetics-announces-three-year-exclusive-partnership-elite-dna/?utm_source=openai))
Geographically, Neuronetics remains heavily U.S.-focused, with the United States as its core commercial market and the main source of revenue. The company’s most recent updates underscore continued domestic execution: in the first quarter of 2026, Neuronetics reported revenue growth, higher U.S. clinic revenue, more NeuroStar systems shipped in the U.S., and improved operating cash outflow versus the prior year. For investors, the stock represents a specialized healthcare name on NASDAQ with exposure to reimbursement trends, clinical adoption, and the execution risk typical of a commercial-stage medtech company. ([ir.neuronetics.com](https://ir.neuronetics.com/news-releases/news-release-details/neuronetics-reports-first-quarter-2026-financial-and-operating?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
